Short Interest in Fidelity Disruptive Medicine ETF (NASDAQ:FMED) Expands By 31.0%

Fidelity Disruptive Medicine ETF (NASDAQ:FMED) saw a large increase in short interest in February. As of February 13th, there was short interest totaling 3,548 shares, an increase of 31.0% from the January 29th total of 2,708 shares. Based on an average daily volume of 6,498 shares, the short-interest ratio is presently 0.5 days. Approximately 0.2% of the shares of the stock are short sold. Approximately 0.2% of the shares of the stock are short sold. Based on an average daily volume of 6,498 shares, the short-interest ratio is presently 0.5 days.

Fidelity Disruptive Medicine ETF Stock Performance

FMED traded down $0.43 during trading on Tuesday, reaching $25.58. 7,889 shares of the company traded hands, compared to its average volume of 7,327. The company has a market cap of $58.83 million, a P/E ratio of 41.33 and a beta of 1.00. Fidelity Disruptive Medicine ETF has a 12-month low of $20.69 and a 12-month high of $29.07. The firm has a fifty day simple moving average of $26.82 and a 200 day simple moving average of $26.34.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Glass Jacobson Investment Advisors llc lifted its position in shares of Fidelity Disruptive Medicine ETF by 44.0% in the fourth quarter. Glass Jacobson Investment Advisors llc now owns 1,260 shares of the company’s stock worth $34,000 after buying an additional 385 shares in the last quarter. Jane Street Group LLC increased its stake in Fidelity Disruptive Medicine ETF by 0.8% in the 1st quarter. Jane Street Group LLC now owns 66,382 shares of the company’s stock worth $1,567,000 after acquiring an additional 499 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Fidelity Disruptive Medicine ETF during the 4th quarter worth approximately $228,000. Vise Technologies Inc. bought a new position in shares of Fidelity Disruptive Medicine ETF during the 4th quarter valued at approximately $234,000. Finally, BXM Wealth LLC bought a new position in shares of Fidelity Disruptive Medicine ETF during the 4th quarter valued at approximately $243,000.

About Fidelity Disruptive Medicine ETF

The Fidelity Disruptive Medicine ETF (FMED) is an exchange-traded fund that mostly invests in health care equity. The fund is an actively managed fund that invests in companies involved in disruptive innovation in Health Care. The fund invests in securities of domestic and foreign issuers FMED was launched on Apr 16, 2020 and is managed by Fidelity.